Research

Hormonal

Pharmacological inhibition or genetic ablation of enzymes controlling sphingolipid synthesis (specifically Serine Palmitoyltransferase and Dihydroceramide Desaturase 1) ameliorates insulin resistance, atherosclerosis, and cardiomyopathy in rodent models.

This research suggests that the type of fat you consume matters more than just the total amount, specifically regarding how it affects your body's insulin sensitivity. Saturated fats appear to trigger the production of specific lipids (ceramides) that block insulin action, contributing to metabolic disease. While this is proven in animals, it implies that dietary quality, particularly the ratio of saturated to unsaturated fats, is a critical lever for metabolic health.

GoodSupportsHIGH confidence
researchers have found that pharmacological inhibition or genetic ablation of enzymes controlling sphingolipid synthesis in rodents ameliorates each of these conditions.
William L. Holland et al. · Endocrine Reviews · 2008

Why this rating

Strong evidence from multiple in vivo rodent models (knockout mice, pharmacological inhibition) showing consistent beneficial effects, though human data is observational/correlational.

Source

Sphingolipids, Insulin Resistance, and Metabolic Disease: New Insights from in Vivo Manipulation of Sphingolipid Metabolism

William L. Holland et al. · Endocrine Reviews · 2008

DOI 10.1210/er.2007-0025

narrative_reviewCited 576×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →